Urine test identifies more than nine in ten bladder cancers, clinical study finds
New research has found that more than 9 in 10 patients with bladder cancer were identified through a noninvasive urine test after urgent referral. The study, led by the University of Birmingham and Nonacus Ltd., involved 964 patients across seven NHS urology departments to examine the real-world significance of testing for bladder cancer using a commercially available urine test. GALEAS™ Bladder,…
A recent clinical study conducted by researchers from the University of Birmingham and Nonacus Ltd. has revealed that a noninvasive urine test can accurately identify over 90% of bladder cancer cases. The GALEAS™ Bladder test, which analyzes genomic information from a patient's urine, detected 92.2% of the 77 bladder cancers present among 964 patients referred urgently to seven NHS urology departments.
The test successfully identified all 17 muscle-invasive bladder cancers and 97.2% of high-grade cancers. Additionally, for patients with non-visible hematuria, the GALEAS Bladder test identified all bladder cancers with a 100% probability of accuracy. Professor Richard Bryan, a co-author of the study, highlighted the potential of the test to help clinicians decide which patients require urgent cystoscopy and which can safely delay the procedure.
The study also showed that incorporating urine-based testing in bladder cancer pathways could reduce the number of urgent cystoscopies by 730 per 1,000 patients without compromising clinical benefits.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
